Pharmacokinetics and -dynamics of needlefree apomorphine administration vs. subcutaneous injections with apomorphine in patients with Parkinson*s disease; a pilot study with a new device
Completed
- Conditions
- Parkinson's Disease10028037
- Registration Number
- NL-OMON35723
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Diagnosed Parkinson's Disease according to UK brain bank criteria;Current usage of Apo-go injector;Not satisfied with the current injection pen
Exclusion Criteria
Participation in other trials;Dependent on dopaminergic medication at night;Severe cognitive pathology, making it difficult to understand the study procedures
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Pharmacokinetic parameters of apomorphine (measured at t=0,<br /><br>3,6,9,12,15,20,30,45,60,90 minutes) - Absorption/elimination halflifes, AUC,<br /><br>Cmax and Tmax. - Concentration-effect relationship of the NAS vs. Apo-go </p><br>
- Secondary Outcome Measures
Name Time Method <p>Timed Up and Go test AE questionnaire Qualitative Erythema Scale Minolta<br /><br>erythema assessment 5-point Satisfaction Scale </p><br>